Back to results
US 11,078,280 B2Granted
Oncolytic viral delivery of therapeutic polypeptides
AssigneeOncorus, Inc.
InventorsLuke Evnin, Mitchell H. Finer
Life of this patent
Estimating the term…
Abstract
Described herein are pseudotyped oncolytic viruses comprising nucleic acids encoding an engager molecule. In some embodiments, the pseudotyped oncolytic viruses comprises nucleic acids encoding an engager molecule and one or more therapeutic molecules. Pharmaceutical compositions containing the pseudotyped oncolytic virus and methods of treating cancer using the pseudotyped oncolytic viruses are further provided herein.
Claims13
An oncolytic herpes simplex virus (HSV) comprising a recombinant nucleic acid comprising:
- i) a first nucleic acid sequence encoding a polypeptide comprising a first domain specific for an antigen expressed on an effector cell and a second domain that hinds to an antigen expressed on a target cell, wherein the antigen expressed on the target cell is FAP, PDL1 or CD47, and wherein the antigen expressed on the effector cell is CD3, CD16 or NKp46, and ii) a second nucleic acid sequence encoding an immune modulator polypeptide selected from the group consisting of a cytokine, a costimulatory molecule, an immune checkpoint polypeptide, an anti-angiogenesis factor, and a matrix metalloprotease (MMP).
Dependencies are inferred from the claim text.